Background: SHARP1 and SHARP2 transcription factors regulate different molecular mechanisms through different signaling pathways. However, their roles in different types of cancer are different. In breast cancer, the tumor-promoting or inhibiting effects of SHARP1 and SHARP2 have not been clearly defined. In this context, we for the first time assessed the predictive role of SHARP1/2 transcription factors in breast cancer patients undergoing neoadjuvant chemotherapy.
Methods: Twenty-five breast cancer patients and twenty-five healthy women were included in our study. In breast cancer patients receiving neoadjuvant therapy, blood samples were obtained at diagnosis and after neoadjuvant chemotherapy. Changes in SHARP1 and SHARP2 expression levels were analyzed by RT-PCR analysis and compared with clinicopathological parameters.
Results: Elevated expression level of SHARP1 was analyzed in breast cancer patients, whereas SHARP2 mRNA level was downregulated at diagnosis compared to the healthy group. However, the expression level of SHARP2 was increased in patients after neoadjuvant chemotherapy. Additionally, a significant difference between SHARP2 level and complete response to neoadjuvant therapy was found (p < 0.05).
Conclusion: Our findings suggest that SHARP1 and SHARP2 could be acted as tumor suppressors in breast cancer patients receiving neoadjuvant therapy. Additionally, changes in the SHARP2 expression level could be a predictive biomarker for neoadjuvant therapy response. However, further molecular studies should be required to assess the predictive role of especially SHARP2 in a large number of breast cancer patients. ORCID NO: 0000-0002-8041-198X
Anahtar Kelimeler: Breast cancer patients, SHARP1, SHARP2, Neoadjuvant chemotherapy.
|
